PT  - JOURNAL ARTICLE
AU  - Vinall, Phil
TI  - CABP Due to MRSA and Treatment with Ceftaroline: Experience from the CAPTURE Study
DP  - 2012 Dec 01
TA  - MD Conference Express
PG  - 17--17
VI  - 12
IP  - 14
4099  - http://mdc.sagepub.com/content/12/14/17.1.short
4100  - http://mdc.sagepub.com/content/12/14/17.1.full
AB  - There is a need for new antibiotics to treat the rising incidence of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections caused by Gram-positive bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, including the multidrug resistant and methicillin-resistant (MRSA) forms of these bacteria. This article presents a poster [Jandourek et al. ICAAC 2012 L1–300c] with results from the Clinical Assessment Program and Teflaro® Utilization Registry cohort [CAPTURE] study that showed ceftaroline produced good clinical outcomes when used as monotherapy to treat CABP due to MRSA.